X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-bowel-disease-drug-fails-meet-main-goal-late-stage-study-2024-03-28/
https://www.fiercepharma.com/marketing/bristol-myers-squibbs-zeposia-abbvies-skyrizi-rinvoq-shaking-early-ibd-treatment-market
https://www.europeanpharmaceuticalreview.com/news/174996/nice-recommends-first-oral-s1p-receptor-modulator-for-ulcerative-colitis/
https://www.upi.com/Health_News/2021/09/30/inflammatory-bowel-disease-medication-multiple-sclerosis/1021632950820/?u3L=1
https://www.pharmaceutical-technology.com/news/nice-rejects-ozanimod-ms/
http://www.pharmatimes.com/news/nice_no_for_bms_multiple_sclerosis_drug_zeposia_1361753
https://www.biospace.com/article/releases/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-zeposia-ozanimod-for-the-treatment-of-ulcerative-colitis-/
https://www.practiceupdate.com/content/acg-2017-ozanimod-maintains-efficacy-and-safety-up-to-2-years-in-moderate-to-severe-ulcerative-colitis/59530
https://www.fiercepharma.com/pharma/bristol-myers-squibb-s-zeposia-boosts-remission-rates-over-placebo-ulcerative-colitis
https://www.biospace.com/article/releases/health-canada-approves-zeposia-and-174-an-oral-treatment-for-relapsing-remitting-multiple-sclerosis/
https://seekingalpha.com/news/3619333-bristol-myers-to-present-late-stage-results-on-ulcerative-colitis-med-ozanimod-october-12
https://investors.bms.com/iframes/press-releases/press-release-details/2020/Bristol-Myers-Squibb-Announces-Interim-Results-from-Long-Term-Study-Reinforcing-Efficacy-and-Safety-Profile-of-Zeposia-ozanimod-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspx
https://www.fiercepharma.com/marketing/bristol-myers-squibb-s-zeposia-launches-into-crowded-multiple-sclerosis-market-amid-covid
https://www.ema.europa.eu/en/documents/overview/zeposia-epar-medicine-overview_en.pdf
https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-positive-chmp-opinion-recommen-4
https://www.citizentribune.com/news/business/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of/article_5584628a-ced3-59d7-83e5-e1e995dc60f6.html
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020
https://endpts.com/bristol-myers-bags-its-blockbuster-fda-ok-for-ozanimod-as-a-long-and-winding-rd-road-finally-ends-in-the-marketplace/
https://www.europeanpharmaceuticalreview.com/news/114882/ten-drugs-in-pre-registration-likely-to-be-blockbusters-by-2025-finds-report/
https://endpts.com/jj-phiii-data-promise-drug-launch-into-crowded-ms-market/
https://www.fiercepharma.com/marketing/lift-off-celgene-ms-awareness-effort-launches-hot-air-balloon-to-highlight-brain-health
https://www.fiercepharma.com/pharma/bms-celgene-deal-gets-another-boost-as-fda-accepts-ozanimod-ms-filing
https://endpts.com/celgene-can-breathe-a-sigh-of-relief-as-fda-accepts-once-spurned-ozanimod-application-setting-a-target-date-on-a-blockbuster-decision/
https://www.fiercebiotech.com/biotech/a-much-needed-positive-for-bms-celgene-gains-fda-review-for-blockbuster-hopeful
https://www.fiercepharma.com/marketing/patient-entrepreneur-finalists-chosen-celgene-and-lyfebulb-ms-innovation-challenge
https://seekingalpha.com/article/4252458-refiling-nda-celgene-major-step-forward-toward-2-potential-approvals
https://www.businesswire.com/news/home/20190325005794/en/Celgene-Submits-Application-FDA-Ozanimod-Treatment-Relapsing/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
http://www.pmlive.com/pharma_news/celgene_hopes_for_second_time_lucky_for_ozanimod_fda_filing_1282622
https://www.fiercebiotech.com/biotech/celgene-s-ms-drug-ozanimod-gets-eu-filing-fda-submission-to-follow
https://endpts.com/with-its-rep-on-the-line-celgenes-newly-filed-safety-study-spurs-fresh-worries-over-fate-of-ozanimod/
https://seekingalpha.com/article/4194116-6-reasons-celgene-remains-best-valued-large-cap-pharma-stock
https://www.biopharmadive.com/news/gilenya-patent-decision-gives-ms-market-a-reprieve/527758/
https://endpts.com/blame-the-ozanimod-fiasco-on-the-receptos-team-just-wait-a-sec-says-ex-ceo-who-sold-the-company-to-celgene-for-7-2b/
https://endpts.com/top-celgene-exec-pins-the-blame-for-ozanimod-fiasco-on-the-receptos-team-acquired-3-years-ago/
https://endpts.com/celgene-works-to-calm-down-anxious-investors-promising-to-re-file-ozanimod-at-the-fda-in-early-2019/
https://endpts.com/celgenes-disclosures-about-ozanimod-this-week-spur-analysts-fears-of-a-lengthy-delay-for-a-key-drug/
Market Place
Share 
